

Does hypothyroidism induced by thyroid hormone withdrawal lead to permanent modifications of the DNA?

Gepubliceerd: 30-07-2019 Laatst bijgewerkt: 13-12-2022

Thyroid hormone withdrawal leads to permanent DNA modifications that are not seen in patients treated with rhTSH.

| | |
|-----------------------------|---|
| Ethische beoordeling | Positief advies |
| Status | Werving gestart |
| Type aandoening | - |
| Onderzoekstype | Observationeel onderzoek, zonder invasieve metingen |

Samenvatting

ID

NL-OMON20919

Bron

NTR

Verkorte titel

Epigenetic DNA modifications due to hypothyroidism

Aandoening

Patients with differentiated thyroid cancer

Ondersteuning

Primaire sponsor: Erasmus MC

Overige ondersteuning: Genzyme Europe B.V.

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Toelichting onderzoek

Achtergrond van het onderzoek

Introduction

Hypothyroidism is one of the most common endocrine disorders. Despite adequate restoration of euthyroidism with LT4, a substantial part of patients (~10-15%) display significant impairment of psychological well-being compared to matched controls. The same holds true for patients who have been treated for differentiated thyroid cancer (DTC). We speculate that the decreased QoL in DTC patients is due to the episode of hypothyroidism, induced by thyroid hormone withdrawal. Epigenetic modifications of the DNA of patients with a history of hypothyroidism are likely to affect thyroid hormone signaling for the rest of their lives.

Objective

To study if thyroid hormone withdrawal leads to permanent DNA modifications that are not seen in patients treated with recombinant human (rh)TSH.

Study Design

Within our Academic Center for Thyroid Diseases, we are prospectively collecting repeated DNA and serum of patients treated with DTC before, during and after treatment with radioactive iodine, either augmented via thyroid hormone withdrawal or rhTSH. We will study if DNA methylation is affected by thyroid hormone withdrawal in genomic DNA of these patients, and if these changes persist after LT4 supplementation. Patients treated with rhTSH will be used as a control, since these patients undergo the same surgery and treatment with radioactive iodine, but do not become hypothyroid

Study Population

Patients, aged 18-80 years, treated with DTC before, during and after treatment with radioactive iodine, either augmented via thyroid hormone withdrawal or rhTSH.

Primary Endpoint

Epigenetic DNA modifications (does thyroid hormone withdrawal result in epigenetic modifications, and if so, do these epigenetic modifications persist after restoring euthyroidism?).

Anticipated Result

Thyroid hormone withdrawal leads to permanent epigenetic DNA modifications that are not seen in patients treated with rhTSH.

Doel van het onderzoek

Thyroid hormone withdrawal leads to permanent DNA modifications that are not seen in

patients treated with rhTSH.

Onderzoeksopzet

3

Contactpersonen

Publiek

Erasmus MC
Anneke Hokke

0031107044986

Wetenschappelijk

Erasmus MC
Anneke Hokke

0031107044986

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Have the capacity to understand and willingness to sign an informed consent form
2. Planned for total thyroidectomy because of differentiated thyroid cancer
3. Aged 18-80 years

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Alcohol abuse
2. Other malignancy
3. Clinically relevant active systemic disease (such as autoimmune or infectious diseases)
4. Pregnancy
5. Use drugs interfering with thyroid hormone metabolism (e.g. antiepileptic drugs,

amiodarone,
and lithium)
6. Other primary thyroid disease

Onderzoeksopzet

Opzet

| | |
|------------------|---|
| Type: | Observationeel onderzoek, zonder invasieve metingen |
| Onderzoeksmodel: | Parallel |
| Toewijzing: | Niet-gerandomiseerd |
| Blinding: | Open / niet geblindeerd |
| Controle: | Geneesmiddel |

Deelname

| | |
|-------------------------|----------------------|
| Nederland | |
| Status: | Werving gestart |
| (Verwachte) startdatum: | 01-05-2016 |
| Aantal proefpersonen: | 20 |
| Type: | Verwachte startdatum |

Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)

Wordt de data na het onderzoek gedeeld: Nee

Ethische beoordeling

| | |
|-----------------|------------------|
| Positief advies | |
| Datum: | 30-07-2019 |
| Soort: | Eerste indiening |

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

| Register | ID |
|-----------------|---------------------------------|
| NTR-new | NL7914 |
| Ander register | METC Erasmus MC. : MEC-2012-561 |

Resultaten